Celina Afonso

Prevalence of measurable residual disease in patients with refractory/relapsed multiple myeloma who reached complete response: a cross-sectional multicentric study

Manuel Neves, Rita Gerivaz, Graça Esteves, Rui Bergantim et autres

Background Multiple myeloma (MM) is an incurable hematologic malignancy, and even though the complete response (CR) rate has been growing, a high percentage of patients continues to relapse. Recent research showed that most relapses may be related to the persistence of measurable …

pt (code pays fourni par la source)

Predicting Caregiver Burden in Multiple Myeloma: Insights from the Carmma Study Using Machine Learning Models

Carlos da Silva Costa, Adriana Roque, João Santinha, Manuel Neves et autres

Introduction Multiple Myeloma (MM) has a significant impact on the quality of life (QoL) of patients and is associated with psychological, physical, social and financial stress on caregivers. Our previous work showed that older age, poor fitness, advanced disease stage and a …

pt (code pays fourni par la source)

Assessment of Multiple Myeloma-Related Burden on Caregivers - a Portuguese National Study

Carlos BT Costa, Manuel Neves, Adriana Roque, Ana Bela Sarmento‐Ribeiro et autres

Introduction Multiple Myeloma (MM) is an incurable hematological cancer that decreases the quality of life of patients but also that of their providers. The disease course is linked with psychological stress of caregivers, but the data on the association between MM characteristics, …

pt (code pays fourni par la source)

P-078 MRDeep study: measurable residual disease rates in patients with multiple myeloma who achieved complete response in 2nd or 3rd lines of treatment

Manuel Neves, Rita Gerivaz, Graça Esteves, Rui Bergatim et autres

Recomendações do Grupo Português do Mieloma Múltiplo para Tratamento do Mieloma Múltiplo

Cristina João, Rui Bergantim, Joana Santos, Celina Afonso et autres

The treatment of multiple myeloma has profoundly changed with the introduction of several innovative therapies. The optimization of therapeutic sequencing through the combined use of the various drugs developed in recent years and the attention given to the characteristics of patients have …

pt, cu, ar (code pays fourni par la source)

PB2117: TEN-YEAR SINGLE CENTER EXPERIENCE TREATING PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: CAN RADIOTHERAPY BE OMITTED?

Ines L Goncalves, Guadalupe Ferreira Gomes, Luís Rodrigues, P. Lupi et autres

Background: Primary central nervous system lymphoma (PCNSL) is a rare form of lymphoma confined to the central nervous system (CNS) that is characterized by an aggressive course, high rates of treatment resistance and short overall survival. In recent decades, the treatment of …

pt (code pays fourni par la source)

Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma

Joana Ferra, Filipa Mousinho, Francisca Miranda, Sandra André et autres

Primary effusion lymphoma is a rare and aggressive large B-cell lymphoma presenting as malignant effusion with poor prognosis. Although it is more prevalent among HIV patients, it has also been described in non-HIV immunocompromised individuals. Given its rarity, there are no large …

pt (code pays fourni par la source)

Aggressive systemic mastocytosis: a silent enemy.

Joana Vaz, Celina Afonso, Rita Sampaio

Mastocytosis results from the accumulation, proliferation and activation of mast cells with the involvement of several organs. The skin, bone marrow, gastrointestinal tract, liver, spleen and lymph nodes are the most frequent locations. Symptoms result from the accumulation of mast cells and …

Multiple myeloma in elderly patients—a Portuguese multicentric real-life study

Cristina João, Rui Bergantim, Manuel Neves, Sérgio Chacim et autres

pt (code pays fourni par la source)

Endomyocardial Fibrosis With End-Stage Heart Failure as a Consequence of a Myeloproliferative Neoplasm With Hypereosinophilia

C Strong, João Abecasis, Celina Afonso, M Trabulo et autres

pt (code pays fourni par la source)

V280G Mutation, Potential Role in Imatinib Resistance: First Case Report

Ana Paula Azevedo, A. Reichert, Celina Afonso, Maria D Alberca et autres

Sage Perspectives Blog focuses on highlighting topical and interesting research published in Sage books and journals. The blog includes posts from authors across a wide range of subject disciplines and research areas.

BCR-ABL V280G Mutation, Potential Role in Imatinib Resistance: First Case Report

Ana Paula Azevedo, A. Reichert, Celina Afonso, Maria D Alberca et autres

Introduction: The identification of BCR-ABL expression as the defining leukemogenic event in chronic myeloid leukemia (CML) and the introduction of BCR-ABL tyrosine kinase inhibitors in 2001 have revolutionized disease management, leading to a reduction in mortality rates and accordingly an increase in …

pt (code pays fourni par la source)